A wave of recent biosimilar launches in the US has led to competition from multiple challengers on several major brands, with the potential to give a major boost to the country’s biosimilars market, AmerisourceBergen’s senior director of biosimilars, Sean McGowan, tells Generics Bulletin in this exclusive Q&A.
Editor’s note: this Q&A was conducted shortly before Merck & Co’s recent launch of Samsung Bioepis’ Ontruzant (trastuzumab-dttb), representing the...






